AU2014327235B2 - New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors - Google Patents

New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors Download PDF

Info

Publication number
AU2014327235B2
AU2014327235B2 AU2014327235A AU2014327235A AU2014327235B2 AU 2014327235 B2 AU2014327235 B2 AU 2014327235B2 AU 2014327235 A AU2014327235 A AU 2014327235A AU 2014327235 A AU2014327235 A AU 2014327235A AU 2014327235 B2 AU2014327235 B2 AU 2014327235B2
Authority
AU
Australia
Prior art keywords
alkyl
group
hydrogen
substituted
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014327235A
Other languages
English (en)
Other versions
AU2014327235A1 (en
Inventor
David Edward Clark
George Hynd
Janusz Jozef Kulagowski
Calum Macleod
Samuel Edward MANN
John Gary Montana
Stephen Colin PRICE
Fabien Jean Ghislain ROUSSEL
Patrizia Tisselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2014327235A1 publication Critical patent/AU2014327235A1/en
Application granted granted Critical
Publication of AU2014327235B2 publication Critical patent/AU2014327235B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
AU2014327235A 2013-09-26 2014-09-25 New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors Ceased AU2014327235B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13186148.6 2013-09-26
EP13186148 2013-09-26
EP14176125.4 2014-07-08
EP14176125 2014-07-08
PCT/EP2014/070489 WO2015044269A1 (en) 2013-09-26 2014-09-25 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publications (2)

Publication Number Publication Date
AU2014327235A1 AU2014327235A1 (en) 2016-03-17
AU2014327235B2 true AU2014327235B2 (en) 2018-02-08

Family

ID=51626028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014327235A Ceased AU2014327235B2 (en) 2013-09-26 2014-09-25 New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors

Country Status (14)

Country Link
US (1) US9981963B2 (enExample)
EP (1) EP3049412B1 (enExample)
JP (1) JP6404332B2 (enExample)
KR (1) KR102317335B1 (enExample)
CN (1) CN105579452B (enExample)
AU (1) AU2014327235B2 (enExample)
BR (1) BR112016006232B1 (enExample)
CA (1) CA2922633C (enExample)
EA (1) EA028101B1 (enExample)
ES (1) ES2643070T3 (enExample)
IL (1) IL244702B (enExample)
MX (1) MX365739B (enExample)
TW (1) TWI627173B (enExample)
WO (1) WO2015044269A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US10323045B2 (en) 2014-10-23 2019-06-18 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as NIK inhibitors
KR102499862B1 (ko) * 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
SI3405196T1 (sl) 2016-01-22 2020-03-31 Janssen Pharmaceutica Nv Novi substituirani derivati cianoindolina kot inhibitorji NIK
CA3027416A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2020162638A1 (ja) * 2019-02-08 2020-08-13 学校法人近畿大学 悪性腫瘍疾患の改善用組成物
RS66105B1 (sr) 2019-05-31 2024-11-29 Janssen Pharmaceutica Nv Inhibitori malih molekula nf-kb koji indukuju kinazu
CN110156766A (zh) * 2019-06-04 2019-08-23 南京工业大学 一种银催化的氘代五元芳香杂环化合物的制备方法
JPWO2022138735A1 (enExample) 2020-12-22 2022-06-30
TW202402269A (zh) * 2022-05-26 2024-01-16 大陸商迪哲（江蘇）醫藥股份有限公司 ＲＯＣＫ（Ｒｈｏ相關激酶）抑制劑及其用途
EP4566599A1 (en) 2022-08-02 2025-06-11 Kinki University Pharmaceutical composition for ameliorating allergic diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
CA2564356A1 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) * 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN103476768B (zh) * 2011-03-16 2015-07-08 弗·哈夫曼-拉罗切有限公司 6,5-杂环炔丙醇化合物及其用途
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
US10323045B2 (en) 2014-10-23 2019-06-18 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as NIK inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
IL244702A0 (en) 2016-04-21
TWI627173B (zh) 2018-06-21
EA028101B1 (ru) 2017-10-31
BR112016006232B1 (pt) 2022-11-29
US9981963B2 (en) 2018-05-29
EP3049412A1 (en) 2016-08-03
KR20160060054A (ko) 2016-05-27
BR112016006232A2 (pt) 2017-08-01
JP2016531858A (ja) 2016-10-13
CA2922633A1 (en) 2015-04-02
ES2643070T3 (es) 2017-11-21
MX365739B (es) 2019-06-12
CA2922633C (en) 2022-07-26
AU2014327235A1 (en) 2016-03-17
JP6404332B2 (ja) 2018-10-10
CN105579452A (zh) 2016-05-11
EA201690657A1 (ru) 2016-08-31
CN105579452B (zh) 2018-01-23
KR102317335B1 (ko) 2021-10-26
TW201602103A (zh) 2016-01-16
US20160229851A1 (en) 2016-08-11
EP3049412B1 (en) 2017-07-12
MX2016003863A (es) 2016-08-04
WO2015044269A1 (en) 2015-04-02
IL244702B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
AU2014327235B2 (en) New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors
AU2014259477B2 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
AU2015334916B2 (en) New pyrazole derivatives as NIK inhibitors
AU2014327233B2 (en) New 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors
AU2015334914B2 (en) New thienopyrimidine derivatives as NIK inhibitors
AU2015334915B2 (en) New pyrazolopyrimidine derivatives as NIK inhibitors
AU2015334917B2 (en) New compounds as NIK inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired